Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Inventor:
Cooper; Eugene R.
Address:
Berwyn, PA
No. of patents:
28
Patents:












Patent Number Title Of Patent Date Issued
8124057 Propellant-based nanoparticulate dry powder aerosols and method of making February 28, 2012
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na
7763278 Nanoparticulate polycosanol formulations and novel polycosanol combinations July 27, 2010
The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosan
7695739 In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or April 13, 2010
Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
7585517 Transscleral delivery September 8, 2009
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these
7521068 Dry powder aerosols of nanoparticulate drugs April 21, 2009
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na
7390505 Nanoparticulate topiramate formulations June 24, 2008
The present invention is directed to nanoparticulate compositions comprising topiramate. The topiramate particles of the composition have an effective average particle size of less than about 2 microns.
7198795 In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of April 3, 2007
Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
6908626 Compositions having a combination of immediate release and controlled release characteristics June 21, 2005
Disclosed are compositions exhibiting a combination of immediate release and controlled release characteristics. The compositions comprise at least one poorly soluble active ingredient having a nanoparticulate particle size, at least one surface stabilizer adsorbed onto the surface of th
6811767 Liquid droplet aerosols of nanoparticulate drugs November 2, 2004
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The na
5853713 Biologically compatible linear block copolymers of polyalkylene oxide and peptide units December 29, 1998
A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.
5705194 Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological January 6, 1998
There is disclosed a pharmaceutical composition which gels at physiological temperature. The composition is comprised of a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy (higher alkylene) blocks wherein at least some of the blocks are linked togethe
5620677 Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointesti April 15, 1997
Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups ca
5618528 Biologically compatible linear block copolymers of polyalkylene oxide and peptide units April 8, 1997
A linear block copolymer comprising units of an alkylene oxide, linked to units of peptide via a linking group comprising a --CH.sub.2 CHOHCH.sub.2 N(R)-- moiety, is useful as an imaging agent, drug, prodrug or as a delivery system for imaging agents, drugs or prodrugs.
5585108 Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically ac December 17, 1996
Nanoparticulate crystalline therapeutic substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.
5565188 Polyalkylene block copolymers as surface modifiers for nanoparticles October 15, 1996
There is disclosed a composition containing nanoparticles having a surface modifier wherein the surface modifier is a block copolymer containing one or more polyoxyethylene blocks and one or more polyoxy(higher alkylene) blocks wherein at least some of the blocks are linked together by a
5531979 Compositions of iodophenoxy alkanes and iodophenyl ethers and pharmaceutically acceptable clays July 2, 1996
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising iodophenoxy alkanes and iodophenyl ethers as the x-ray producing agents in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier;
5484585 Compositions of iodobenzoic acid derivatives and pharmaceutically acceptable clays for visualiza January 16, 1996
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising iodobenzoic acid derivatives as the x-ray producing agents in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and method
5472682 Compositions of iodophenyl esters and iodophenyl sulfonates and pharmaceutically acceptable clay December 5, 1995
Disclosed are x-ray contrast compositions of the formula ##STR1## wherein X is ##STR2## or --SO.sub.2 --; Z is H, halo, methyl, ethyl, n-propyl, C.sub.4 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups can be substituted with halogen or
5466440 Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharm November 14, 1995
Nanoparticulate crystalline substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline substances and the gastrointestinal tract. These formulations have improved safety profiles, a low potential for absorption, are not vis
5466440 Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharm November 14, 1995
Nanoparticulate crystalline substances formulated with stabilizers and pharmaceutically acceptable clays to enhance contact between the crystalline substances and the gastrointestinal tract. These formulations have improved safety profiles, a low potential for absorption, are not vis
5451393 X-ray contrast compositions useful in medical imaging September 19, 1995
An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an
5424056 X-ray contrast compositions containing iodoaniline derivatives and pharmaceutically acceptable c June 13, 1995
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising an iodoaniline derivative as the x-ray producing agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods fo
5368837 X-ray contrast compositions containing an organic crystalline X-ray contrast agent and a cellulo November 29, 1994
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a crystalline contrast agent in a pharmaceutically acceptable carrier comprising a cellulose derivative; and methods for their use in diagnostic radiology of the gast
5360604 X-ray contrast compositions containing an organic crystalline X-ray contrast agent in combinatio November 1, 1994
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a crystalline organic constrast agent in combination with a pharmaceutically acceptable clay in a pharmaceutically acceptable carrier; and methods for their use in di
5326553 Compositions of iodophenoxy alkanes and iodophenyl ethers in film-forming materials for visualiz July 5, 1994
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material capable of forming a coating on the gastrointestinal tract and an x-ray producing agent of the formula ##STR1## and methods for their use in
5318768 Polymeric x-ray contrast compositions containing an organic crystalline x-ray contrast agent June 7, 1994
Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material in combination with a divalent cation capable of forming a coating on the gastrointestinal tract and a crystalline contrast agent in a pharmaceut
5318767 X-ray contrast compositions useful in medical imaging June 7, 1994
An X-ray contrast composition comprising particles consisting essentially of a non-radioactive crystalline organic x-ray contrast agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than 400 nm, an
5316755 Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointesti May 31, 1994
Disclosed are contrast agents of the formula ##STR1## contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract whereinZ=H, halo, C.sub.1 -C.sub.20 alkyl, cycloalkyl, lower alkoxy, cyano, where the alkyl and cycloalkyl groups ca










 
 
  Recently Added Patents
Preferential selection of candidates for delta compression
Fire detector
Device and method for quantizing and inverse quantizing LPC filters in a super-frame
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
Lithographic apparatus and device manufacturing method
Sitagliptin intermediate compounds, preparation methods and uses thereof
Portable electronic device holder and tether
  Randomly Featured Patents
Reservoir body for a radial plunger pump
Method of forming prestressed filament wound pipe
Light emitting diode dental handpiece
Memory locking means for digital exposure control device in cameras
Display apparatus and method of fabricating the same
Gyrotron including quasi-optical mode converter
Laser beam harmonics generator and light exposing device
2-Mercaptopyrimidohexahydroquinolines and related compounds
Method, data structure, and systems for customer segmentation models
Digital broadcasting receiver